 |
|
Neal Gordon, CEO of Epitome
Biosystems
in Waltham,
announced
that his
company has
received a
second SBIR
grant of
$500k to
study
cellular
activity and
drug
responses.
Epitome's
EpiTag
product is
used to
develop
antibody
pairs for
the
measurement
of proteins
and to aid
in drug
discovery.
The story is
reported in
Mass
High Tech,
12/14/06.
Congratulations to Neal and his team on the progress
they are
making in
the
development
of Epitome's
protein-testing
products.
Neal is a member of CEO Roundtable.
|
|
 |
|
The front page of the Sunday Eagle-Tribune (Dec.
10) featured
a story
about and
photos of
Dick Sumberg
and his
wife, Lolli,
working on a
Habitat for
Humanity
house that
they decided
to build in
Lawrence to
commemorate
their 60th
birthdays.
Dick has
been
building
this house
since last
spring. He
recruited
friends,
customers and
fellow CEO
Roundtable
members to
help with
the labor
and contribute
materials
and
construction
services.
Dick has
been giving
his
Roundtable
group
monthly
updates on
the progress
of the
construction.
He is
especially
pleased that
he was able
to do more
than write a
check this
time.
We are proud of what Dick has accomplished and the
example he
has set for
giving back
by using his
back.
Dick Sumberg is a 10 year member of CEO Roundtable.
|
|
 |
Charles Sherwood, CEO of
Anika
Therapeutics,
announced that
the company has
received an
"approvable
letter" from the
FDA which could
mean that the
FDA will soon
approve Anika's
cosmetic
tissue-augmentation
product.
Investors
responded by
bidding up share
prices over
20%. (NASDAQ: ANIK).
For more
details, please
see Boston
Globe,
November 19,
2006, page F5.
This HA based
product is for
use as an
injectable
soft-tissue
filler for
wrinkles, scars,
and lip
augmentation.
Chuck is a
member of one of
the CEO
Roundtables for
biotech/pharma
companies. |
|
 |
Peter Savas, chairman & CEO, Boston Life Sciences, was
interviewed by
R.D. Sahl on
NECN TV's
Business Day
progam. He
reviewed the
status of
clinical trials
for several of
BLS's leading
products,
including
ALTROPANE, a
molecular-imaging
agent that is in
Phase III
trials. It is a
diagnostic tool
intended to aid
in
differentiating
Parkinsonian
tremors from
non-Parkinsonian
or essential
tremors. The
interview can be
seen at
www.necn.com.
Boston Life
Sciences is a
public company
listed on
NASDAQ. See
www.bostonlifesciences.com. |
|
|
 Sarah Fuller's picture is in Mass High Tech,
(Sept. 15-21, p. 19).
She is shown
receiving the CEO
Roundtable Leadership
Award for 2006.
Sarah received this
award for the example
she set in finding the
best buyer for a
majority share of her
company, Decision
Resources, and the
subsequent expansion of
the company to the
benefit of her employees
and customers. Sarah
still owns a substantial
share of the company and
continues to provide the
daily leadership and the
long term vision for the
company. She continues
to build her legacy.
We are very proud to
have Sarah Fuller as a
longtime member of CEO
Roundtable.
PS: We shared the page
in MHT with
photos of Doug Flutie --
good company! |
|
 |
Peter Savas, chairman & CEO, Boston Life Sciences, was
interviewed by
R.D. Sahl on
NECN TV's
Business Day
progam. He
reviewed the
status of
clinical trials
for several of
BLS's leading
products,
including
ALTROPANE, a
molecular-imaging
agent that is in
Phase III
trials. It is a
diagnostic tool
intended to aid
in
differentiating
Parkinsonian
tremors from
non-Parkinsonian
or essential
tremors. The
interview can be
seen at
www.necn.com.
Boston Life
Sciences is a
public company
listed on
NASDAQ. See
www.bostonlifesciences.com. |
|
 |
Mike Dempsey, founder of Radianse, is expanding his
company's
product and
service offering
for hospitals
through a joint
marketing
agreement with
Patient Care
Technology
Systems of
California. The
story is
reported in
Mass High Tech,
Aug 29.
Radianse will
integrate PCTS's
hospital
workflow
software into
its RFID-based
indoor-positioning
and tracking
systems, which
it is installing
at hospitals
across the
country. The
combination of
the products
will provide
fully integrated
work flow
systems to
hospitals,
thereby
improving
patient care and
reducing costs.
Mike is a
long-time member
of the high tech
peer group
within CEO
Roundtable. |
|
 |
Dennis Goldberg, CEO of Transport Pharmaceuticals, is
profiled in the
August 25 issue
of Mass High
Tech (page
18).
The article by
Patricia Resende
describes
Dennis's drive
to build
companies that
develop and
deliver
lifesaving drugs
and
technologies.
He chose Pfizer
over academia
because he
wanted to be
more directly
involved in
delivering new
drugs. The
large corporate
environment
didn't meet his
needs and he
soon moved into
start-up
biotech, working
on the front
lines of
developing
therapies for
AIDS and other
diseases.
Dennis was named
CEO of Transport
Pharmaceuticals
which recently
announced the
continuation of
a significant
relationship
with
GlaxoSmithKline
to test and
market a new
treatment for
herpes. See
www.transportpharma.com.
Great photo,
Dennis! |
|
 |
Walter Ogier, CEO of Arbios,
Inc.,
is pictured in a
Boston Business
Journal
story (8/4/06)
about the
company's
efforts to
develop an
"artificial
liver." Arbios
has developed
HepatAssist, a
external device
that cleans
toxins from the
blood in
patients with
liver disease.
The device is
intended to help
patients until
they can receive
a liver
transplant.
Walter took over
as CEO of the
OTC listed
company last
fall and moved
it to Boston
from
California.
This is a
restart for the
technology,
which has been
improved and
recently
received FDA
approval for new
clinical
trials. See
www.arbios.com. |
|
Walter
Ogier, CEO of
Arbios, Inc.,
is pictured in a
Boston Business
Journal
story (8/4/06) about the
company's efforts to
develop an "artificial
liver." Arbios has
developed HepatAssist, a
external device that
cleans toxins from the
blood in patients with
liver disease. The
device is intended to
help patients until they
can receive a liver
transplant.
Walter took over as CEO
of the OTC listed
company last fall and
moved it to Boston from
California. This is a
restart for the
technology, which has
been improved and
recently received FDA
approval for new
clinical trials. See
www.arbios.com.
Walter is a member of
CEO Roundtable. |
Dennis Goldberg,
CEO,
Transport
Pharmaceuticals,
announced the
company has
closed on
additional
funding of
$12.6m.
Transport
Pharmaceuticals
will use the
funds to
continue
research in
treatment of
herpes labialis
(cold sores).
The company has
developed a drug
delivery
platform based
on a technology
employing a
low-voltage
electrical
charge to
deliver
medications
through the
skin. Patients
can
self-administer
doses of
medication from
pre-filled
cartridges.
The round of
financing was
led by current
investor The
Carlyle Group of
Washington, D.
C. Transport has
raised a total
of $35.6m. The
story is
reported in
MHT, August
1, 2006.
Dennis is a
member of CEO
Roundtable.
Congratulations
to Dennis and
his team on this
significant
milestone. |
|
|
Loren Carlson honors
Sarah W. Fuller with
2006 "CEO Roundtable
Leadership Award" |
|
 CEO Roundtable honored Sarah W. Fuller,
President and
COO of Decision
Resources, Inc.,
on July 12 with
the second
annual "CEO
Roundtable
Leadership
Award."
"The Leadership
Award is given
in recognition
of Sarah's
exemplifying the
power of peer
groups to help
members increase
the value of
their companies
and enrich the
quality of their
lives," Loren G.
Carlson,
Chairman of CEO
Roundtable,
said.
Sarah Fuller is
the president,
chief operating
officer, and
board director
of Decision
Resources Inc.,
one of the
world's leading
research and
advisory firms
focusing on
pharmaceutical
and health care
issues. The
Waltham,
Mass.-based
company is best
known for its
therapeutically
focused analyses
of global
pharmaceutical
and
biotechnology
markets and for
its research on
the U.S. managed
care industry
through its
HealthLeaders-InterStudy
subsidiary. More
than 1,000
clients use
Decision
Resources'
services for
their strategic
planning, market
development,
technology
management,
competitive
intelligence,
and investment
requirements.
Sarah is a very
long-time member
of CEO
Roundtable. In
his remarks
Loren Carlson
stressed that
Sarah is a
leading example
of enlightened
business
leadership. She
has proved that
forgoing short
term personal
financial gain
for other
business values
can increase the
long term
returns for all.
Sarah had
several options
when selling a
majority share
in the company
but she chose
the one that she
believed gave
the company and
the employees
the greatest
chance at
staying focused
on the mission
of providing the
best information
to its
customers.
"Sarah showed us
that you can
have it all --
the resources
for growth and
the freedom to
make the best
long-term
decisions for
everyone," said
Loren.
Several members
of Sarah's
Roundtable peer
group added
their
observations of
why she deserves
the CEO
Roundtable
Leadership
Award, noting
the low employee
turnover, the
strategic
consistency and
the life balance
at Decision
Resources.
Indeed the story
of Sarah Fuller
and Decision
Resources is one
that could
easily have been
included in Bo
Burlingham's
recent book,
Small Giants:
Companies That
Choose to Be
Great Instead of
Big.
Mrs. Fuller's
current
responsibilities
include driving
double-digit
growth in
revenues and
profits for
Decision
Resources, Inc.,
as well as
building new
partnerships
such as their
recent joint
venture with
PharMetrics and
the acquisition
of Millennium
Research Group.
Previously, Mrs.
Fuller was a
vice president
at Arthur D.
Little, Inc., a
consulting firm
with specialties
in many sectors
including
chemical,
pharmaceutical,
and high-tech.
During her 29
years at
Decision
Resources, she
has served 20
years as its
president. In
1990, Sam
Fleming and Mrs.
Fuller led a
buyout of Arthur
D. Little
Decision
Resources from
Arthur D.
Little, Inc.
In 2003,
Castanea
Partners and
Boston Ventures
Limited
Partnership VI
became the
majority
shareholders in
Decision
Resources,
bringing the
added capital
and the
financial and
operating
experience
necessary for
the company to
accelerate its
strategy and
growth. Mrs.
Fuller continues
to serve as its
president, chief
operating
officer, and
board director.
Mrs. Fuller is
on the board of
Cultural
Survival, a
Harvard
University-affiliated
non-profit
organization
that promotes
the vision,
rights and voice
of indigenous
people, and the
Huntsman's
Program at the
University of
Pennsylvania.
She has led
numerous
worldwide
consulting
studies focusing
on management
and strategy
issues within
the
pharmaceutical
industry. Mrs.
Fuller holds a
B.A. from the
University of
Pennsylvania and
an A.M. from
Harvard
University.
Robert M.
Glorioso, a
long-time CEO
Roundtable
member, was the
first recipient
of the CEO
Roundtable
Leadership
Award, given in
recognition of
his outstanding
and illustrious
credentials that
include major
contributions to
computer
hardware and
software
technology
development, and
to honor his
career as a
"serial
entrepreneur." |
|
|
|
Mike Dempsey, Radianse,
recently
announced the
completion of a
$6m round of
financing. The
additional funds
will be used to
fuel the rapid
growth of the
company and new
product
development.
See
Boston Business
Journal,
July 13, 2006.
National
Healthcare
Services led
this round,
which included
returning
investors
Partners
Healthcare, HLM
Venture
Partners,
Partech
International,
Ascension Health
Ventures, and
Kaiser
Permanente.
Radianse is
installing its
RFID based
information
systems in
hospitals around
the country,
including Mass
General and
Brigham &
Women's in
Boston.
Mike is a
longtime member
of CEO
Roundtable.
Congratulations
to Mike and his
team for their
continued
success. |
|
|
|
Charles (Chuck) Sherwood, CEO, Anika
Therapeutics,
announced a
worldwide
development and
commercialization
agreement with
Galderma
Pharmaceutical,
a Swiss company,
for further
development and
marketing of
Anika's tissue
augmentation
therapy and
other cosmetic
products. The
Swiss company is
a joint venture
between Nestle
and L'Oreal.
The news was
reported in Mass
High Tech Flash
Report, July 5,
2006.
This marks
another step
forward in
Anika's
diversification
of its
hyalaronic
acid-based
product line.
Anika
Therapeutics is
a public company
with revenues of
$29.8m in 2005.
See
www.AnikaTherapeutics.com.
Congratulations
to Chuck and his
team. Chuck is
a long time
member of CEO
Roundtable. |
|
 |
Mercia Tapping's company,
AllergyBuyersClub,
was selected by
Boston
Business Journal
as one of the
Best
Places to Work
in the small
business
category.
AllergyBuyersClub.com
sells healthy
home products on
the web and
through a print
catalog, e.g.,
air purifiers,
dehumidifiers,
Hepa vacuums and
hypoallergenic
bedding to meet
the needs of
allergy, asthma,
and sinus
sufferers.
See
www.AllergyBuyersClub.com.
Mercia joined
CEO
Roundtable
when she started
her company in
her home. She
has been
recognized with
several regional
and national
awards for her
success as an
entrepreneur.
Two members of
the Roundtable
serve on
Mercia's board
of advisors.
Congratulations
to Mercia and
her team for
creating a "Best
Place to Work." |
|
 |
Michael Webb, CEO of Ascent
Therapeutics,
has been elected
the next Chair
of the
Mass Biotech
Council.
MBC with over
500 members is
the leading
association for
the
biotechnology
and
pharmaceutical
industry in New
England. As the
Chairman of MBC,
Mike will
oversee MBC's
efforts to
continue the
development of
the life
sciences as the
leading economic
resource for our
area and to
support the
success of the
members. See
www.MassBio.org.
Mike is a long
time member of
CEO
Roundtable.
He was the CEO
of Epix
Pharmaceuticals
for 11 years and
recently founded
Ascent
Therapeutics.
We congratulate
Mike for taking
on this additional
responsibility.
We need people
of Mike's
character and
talent as our
leaders. |
|
 |
Agencourt Personal Genomics of
Beverly, MA
announced that
it has agreed to
sell the company
for $120m to
Applied
Biosystems
in
California. The
purchase was
reported by Mass
High Tech.
Congratulations
to Brian
McKernan,
CEO of Agencourt,
and his team on
the success of
the company. |
|
|
|
Mike Webb
has announced
his plans to
start Ascent
Therapeutics.
Mike is the
former CEO of
Epix
Pharmaceuticals,
a public
company, which
recently merged
with Predix
Pharmaceuticals.
The Boston
Business Journal
(May 20, pg 7)
reports that
Ascent
Therapeuptics
will focus on
oncology and
inflamation
treatments
utilizing new
discoveries at
Tufts-New
England Medical
Center. Mike is
planning to
develop
partnerships
with large
pharmaceutical
companies in
India.
Mike is a long
time member of
CEO Roundtable.. |
|
 |
Kedar Gupta's
company,
GT Solar, a
divison of GT
Equipment in
Merrimack, NH,
has completed
phase one of a
turnkey solar
manufacutring
line for LDK
Solar in China.
Mass High
Tech reports
that LDK Solar's
ultimate plan is
to expand this
to a 1-gigawat
manufacturing
line.
Congratulations
to Kedar and his
team for
achieving this
milestone in
this long term
contract. |
|
 |
AScott
Gillis, the
CEO of
Nucryst
Pharmaceuticals,
is featured in a
Boston Business
Journal
story (April 21,
pg 13) about his
company's plans
to expand after
a successful IPO
which raised
over $42m and
spun it out of
its parent
company.
Nucryst has a
very healthy
revenue stream
from its
antimicrobial
coating products
used to treat
burn victums and
other wounds.
The company will
leverage its
core
nanotechnology
to expand its
product line to
other
therapeutic
areas including
atopic
dermatitis and
gastrointestinal
disorders.
Nucryst's core
technology is
its ability to
dismantal silver
atom by atom and
reassemble it
into differnt
forms of silver
with enhanced
microbial
properties. See
www.nucryst.com.
Scott has been
leading Nucryst
in the succesful
commercialization
of it products
with its
distribution
partner, Smith &
Nephew, and
positioning the
company to
crossover from
medical devices
to
pharmaceuticals.
Scott is long
time member of
CEO Roundtable. |
|
 |
Andrew
Barnett's
new healthy
dessert,
Alpine Ice,
is highlighted
in the food
section of the
Boston Globe,
March 29, C2.
The report says,
"Alpine Ice,
infused with
herbs, fruit,
tea, and all
natural flavors
provides an
option for those
who avoid
sweets, dairy,
egg, soy, wheat,
or nuts".
Andy is
co-founder of
Mountain Herbal
Foods of
Marblehead. The
company created
this very tasty
dessert for
those with
allergies or who
prefer to be
vegan. Alpine
Ice is currently
available only
in Massachusetts
and can be
bought at Whole
Foods Markets
and other
specialty food
stores. For a
current listing
of stores
selling Alpine
Ice go to
www.mtnherbal.com.
Andy is a long
time member of
CEO Roundtable
-- and we have
been his "first
tasters" from
the start. We
served Alpine
Ice at the
recent CEO
Roundtable
Retreat at
Babson College. |
|
 |
Martin Reid,
CEO of
Ibis Technology
in Danvers, MA,
announced that
Sumitomo
Mitsubishi
Silicon Corp,
the world's
second largest
silicon wafer
manufacturer,
has given final
customer
acceptance for
the Ibis i2000
oxygen implanter
AND has
confirmed its
order for a
second $7m
machine. The
story is
reported in
Mass High Tech (MHT)
, March 13.
Ibis Technology
manufactures the
complex machines
that are used to
produce large
silicon wafers
that have oxygen
atoms implanted
to serve a
insulators,
permitting
silicon chips to
run at higher
speeds and at
lower
temperatures.
SUMCO will be
providing the
semiconductor
industry with
chips that will
increase the
speed and
versatility of a
variety of
computers.
Congratulations
to Martin
(Woody) Reid and
his team on the
accomplishment
of this
milestone -- it
has taken years
of perseverance. |
|
|
|
Walter Ogier,
CEO, Arbios
Systems, has
completed a
private
placement of
$1.35m for
continued
development of
the company's
proprietary
liver assist
devices and new
technologies to
be used in the
diagnosis and
treatment of
liver failure.
LibertyView
Capital
Management
led the
investment.
Arbios Systems
trades on Over
the Counter
Bulletin Board.
See
www.arbios.com.
The news is
reported in
Mass High Tech
today.
Walter is a
member of CEO
Roundtable. |
|
|
|
Charles
Sherwood,
CEO, Anika
Therapeutics,
announced that
Anika has
received
approval from
the European
Union to market
Redefyne in
Europe.
Redefyne is
a cosmetic
augmentation
product based on
Anika's
propriety
technology for
chemically
modified
hyaluronic acid
(HA) which can
be injected into
soft tissue for
wrinkles, scar
remediation and
lip
augmentation.
Anika has
applied to the
FDA for
pre-market
approval for
this same
product in the
US. The story is
reported in
Mass High Tech,
Feb 17.
Congratulations
to Chuck and his
team for
achieving
another
milestone in the
commercialization
of their
research,
development and
manufacturing
efforts.
Anika is listed
on NASDAQ. See
www.anikatherapeutics.com
for information
on other Anika
products.
Chuck Sherwood
is a long time
member of CEO
Roundtable. |
|
 |
Sarah Fuller,
co-founder and
President,
Decision
Resources Inc.
in Waltham,
announced the
acquisition of
Millennium
Research Group
in Toronto,
Canada.
Decision
Research Inc is
a global leader
in market
research for the
pharmaceutical
and
biotechnology
industries. DRI
is engaged in an
aggressive
expansion to
build a
portfolio of
services that
provide insight
to customers who
are increasingly
focused on the
junction between
drugs and
devices. The
story is
reported in
Mass High Tech,
Feb 3.
Congratulations
to Sarah and her
team.
Sarah is a long
time member of
CEO Roundtable. |
|
|
|
Scott Gillis,
NUCRYST, goes
public, gets
$46m
Scott Gillis,
CEO, NUCRYST
Pharmaceuticals
in Wakefield
ended the year
with a
successful IPO
on Dec 22, 2005.
This was the
last IPO in the
whole country in
2005 and one of
the few biotech
IPOs in Boston
the whole year.
NUCRYST raised
over $46m. Its
stock is traded
on NASDAQ (NCST)
and Toronto (NCS).
NUCRYST
Pharmaceuticals
was spun out of
Westaim, a
Canadian
company. The
company is
especially well
known for its
burn and wound
dressings that
utilize
nanotechnology
to increase the
healing
properties of
nanocrystalline
silver. The
company has
other products
in the
development
pipeline.
Scott is a
member of CEO
Roundtable --
and we couldn't
be happier for
him and his
team. See
www.nucryst.com.
|
|
 |
Sig Tullmann,
CEO of
Safe Hydrogen,
announced that
the company has
been awarded
$308k to
complete its
work for the
Department of
Energy to
confirm the
functionality,
efficiency and
cost of Safe
Hydrogen's
proprietary
compound to
store, transport
and generate
hydrogen. The
story is
reported in
Mass High Tech
today.
Safe Hydrogen
has developed a
safe, pump able
hydrogen rich
fuel that
releases
hydrogen as
needed. The pump
able hydride
slurry is not
flammable, is
safe to handle,
and is easy to
store in the
current pumps
and tanks used
for diesel fuel,
gasoline or
water. These
characteristics
should help to
overcome one of
the obstacles to
the widespread
use of hydrogen
fuel in motor
vehicles, the
need for a
national
infrastructure
to store and
distribute the
fuel.
Sig is long time
member of CEO
Roundtable. |
|
 |
Kedar Gupta,
Founder and CEO
of GT Equipment
Technologies in
Merrimack, NH
announced the
sale of the
majority
interest in the
company to GFI
Energy Ventures
of Los Angeles.
The company will
continue to
operate in
Merrimack and
Kedar and his
team will
continue to run
the business.
GT Equipment
Technologies is
a world leader
in the design,
construction,
and deployment
of photovoltaic
factories. These
turnkey assembly
lines have been
sold around the
globe with most
of the recent
sales in China,
Taiwan and the
other Asian
countries. GT
has a very large
backlog of
contracts. GT
will use the
funds from the
investors to
continue its
expansion.
This has been a
remarkable story
of the strength
of the
entrepreneurial
spirit. When
Kedar joined CEO
Roundtable he
was facing very
difficult
business
challenges and
the vultures
were circling.
We are all very
proud of Kedar
and what he and
his team
accomplished. It
is a tale worth
the telling.
GFI Energy
Ventures is a
private equity
firm focused on
energy
infrastructure
companies. |
|
 |
David Dove's
company, Aeris
Therpeutics, has
been granted
"Fast-Track"
status by the
FDA for its
non-surgical
treatment of
advanced
emphysema. The
treatment is
called
bronchoscopic
lung volume
reduction (BLVR).
Aeris has
completed Phase
1 trials and the
Fast-Track
designation may
accelerate the
FDA approval
process.
See
www.aerist.com
The story is
reported in Mass
High Tech, Dec
12, page 8.
The FDA
"Fast-Track"
designation is
reserved for
drug and
biological
development
programs that
are intended to
to treat serious
or life
threatening
conditions and
that demonstrate
the potential to
address crucial
medical needs.
David Dove is a
member of one of
the CEO
Roundtables for
biotech
companies. |
|
|
